Restructuring Of China General Technology And Henan Topfond Pharmaceutical Group Delayed
This article was originally published in PharmAsia News
Executive Summary
China General Technology and Henan Topfond Pharmaceutical Group are still waiting for the approval of State-owned Assets Supervision and Administration Commission of the State Council for their restructuring (PharmAsia News, Jun. 2, 2008). According to the agreement, China General Technology will inject the initial funds into Topfond when the business registration changes. The delay is putting pressure on the latter's finances, whose liabilities have hit RMB 1.7 billion. When questioned about whether the deal will go through, Topfond expressed confidence in getting the approval as the restructuring represents transfer between state-owned assets. With total equity of RMB 2.6 billion and net assets of RMB 800 million, the firm's assets-liabilities ratio of 65 percent is still within the normal range. (Click here for more - Chinese Language)
You may also be interested in...
China General Technology To Acquire Henan Topfond Pharmaceutical
Henan Topfond Pharmaceutical Group will be transferring all its stake in Henan Topfond Pharmaceutical to state-owned China General Technology (Group) Holding (Genertec). Topfond Pharmaceutical needs funds urgently, while cash-rich Genertec has no pharmaceutical assets. The latter has been courting another drug company, Huabei Pharmaceutical, for some time but without success. According to sources, Genertec will inject approximately 3 billion yuan into Topfond to incorporate it as a development platform for pharmaceutical business. However, the deal needs the approval of State-owned Assets Supervision and Administration Commission of the State Council. To date, both parties have not signed any official collaboration agreement. (Click here for more - Chinese Language)
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.